Magrolimab + Azacitidine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Sep 8, 2017 → Sep 5, 2023
NCT ID
NCT03248479About Magrolimab + Azacitidine
Magrolimab + Azacitidine is a phase 1 stage product being developed by Gilead Sciences for Hematological Malignancies. The current trial status is terminated. This product is registered under clinical trial identifier NCT03248479. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03248479 | Phase 1 | Terminated |
Competing Products
20 competing products in Hematological Malignancies